Budget Impact Analysis of Dupilumab 200 Mg for Treatment of Adolescent and Adult With Severe Asthma in Algerian Setting

OBJECTIVES: The aim of this study is to estimate the impact of dupilumab 200 mg introduction with existing treatment regimens (SoC) for patients with severe asthma in Algeria

METHODS: The budget impact analysis was designed with a 5-years’ time horizon for adults and adolescents (12 years and older) with severe asthma, comparing two scenarios (market with and without dupilumab) using the epidemiology data references from National Office of Statistics, literature and KoL inputs. The costs included are treatment costs and costs of exacerbation which are covered by the health authorities (PCH and hospitals), representing direct costs related to the management of severe asthma. All costs were reported in Euro. Deterministic sensitivity analysis was carried out on all relevant costs and parameters included in the budget impact assessment.

RESULTS: The results showed a negative budget of (TBI= - 23M Euro) cumulative over the 5 years. The breakdown of the budget impact between therapy initiation and maintain is: - 6 M Euro for treatment initiation, - 17 M Euro for maintain using dupilumab 200mg. Sensitivity analyses determined that the cost of SoC* and eligible population had the potential to impact the base case analysis.

CONCLUSIONS: The total budget for the introduction of dupilumab 200 mg in Algeria has a considerable saving on health expenses on both PCH and hospitals budgets. Hence dupilumab 200 mg as an innovative drug is characterized with beneficial clinical and economic value.

Key words: Dupilumab 200 mg, budget impact, introduction.

Abbreviation: PCH (Central Pharmacy of Hospital), TBI (Total Budget Impact), SoC (Standard of Care = Omalizumab*)

ACKNOWLEDGMENTS: The investigator contribution to the study and Sanofi who funded the study.

DISCLOSURE: no specific disclosure